Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Neutral Aston Martin Lagonda Global Holdings (AML) by Citi
- Buy Glencore (GLEN) by Citi
- Buy London Stock Exchange Group (LSEG) by UBS
- Market Perform WPP (WPP) by Bernstein
- Buy Jet2 (JET2) by UBS
- Sell WPP (WPP) by UBS
- Equal Weight WPP (WPP) by Barclays
- Sell HSBC Holdings (HSBA) by Shore Capital
- Buy Luceco (LUCE) by Deutsche Bank
- Sell Haleon (HLN) by Deutsche Bank
- Buy Man Group (EMG) by Deutsche Bank
- Underweight Ocado Group (OCDO) by Barclays
- Overweight London Stock Exchange Group (LSEG) by Barclays
- Overweight Howden Joinery Group (HWDN) by Barclays
- Buy Man Group (EMG) by Goldman Sachs
- Buy London Stock Exchange Group (LSEG) by Goldman Sachs
- Sector Perform Antofagasta (ANTO) by RBC Capital
- Outperform Hochschild Mining (HOC) by RBC Capital
- Sector Perform Fresnillo (FRES) by RBC Capital
- Outperform Endeavour Mining (EDV) by RBC Capital
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 61 open tips for Shield Therapeutics (STX)
| Latest Bid : 9.50p | Latest Ask : 10.50p |
| High Today : 10.50p | Low Today : 9.50p |
| This Years High : 12.20p | This Years Low : 2.26p |
| Volume : 296,054 | MKT Cap : £82.11M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2019-12-05 11:15:00 05/12/2019 | -96.44% |
| Risky Buy | Malcolm Stacey | Premium Only | 2019-11-12 08:15:00 12/11/2019 | -95.30% |
| Buy | Peel Hunt | Premium Only | 2019-11-04 08:30:00 04/11/2019 | -95.59% |
| Buy | Sabah Meddings | Premium Only | 2019-11-03 10:40:00 03/11/2019 | -95.60% |
| Corporate | FinnCap | Premium Only | 2019-10-23 10:55:00 23/10/2019 | – |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 9.50p | Latest Ask : 10.50p |
| High Today : 10.50p | Low Today : 9.50p |
| This Years High : 12.20p | This Years Low : 2.26p |
| Volume : 296,054 | MKT Cap : £82.11M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2019-12-05 11:15:00 05/12/2019 | -96.44% |
| Risky Buy | Malcolm Stacey | Premium Only | 2019-11-12 08:15:00 12/11/2019 | -95.30% |
| Buy | Peel Hunt | Premium Only | 2019-11-04 08:30:00 04/11/2019 | -95.59% |
| Buy | Sabah Meddings | Premium Only | 2019-11-03 10:40:00 03/11/2019 | -95.60% |
| Corporate | FinnCap | Premium Only | 2019-10-23 10:55:00 23/10/2019 | – |